# Automera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/automera

- Industry: Biotechnology
- Headquarters: Singapore
- Website: www.automeratx.com
- Total disclosed funding: $16M
- Latest round: Series A (Sep 27, 2023)
- Investors on record: 4

## About

Based in Singapore and founded in 2022 by co-founders Michael Lazarou, Loong Wang, and Taiyang Zhang, Automera operates as a biotechnology company that develops therapeutics focused on autophagy-based targeted protein degradation. In September 2023, Automera raised USD 16 million in series A funding co-led by Accelerator Life Science Partners and Clavystbio, with participation from EDBI and Xora Innovation. As of September 2023, the company has offices in Seattle, and Singapore and is led by its CEO Thong Q. Le.   


Automera's flagship product is an AUTAC platform that specializes in designing chimeric small molecules. These molecules possess a dual-binding capability, allowing them to target autophagy processes and specific disease-related molecules. Automera's platform enables treatment across a spectrum of diseases, including cancer, inflammation, and central nervous system disorders.

The company plans to use the series A funding to amplify its development initiatives.

## Funding rounds

- Series A, Sep 27, 2023, $16M — SG Growth Capital, Accelerator Life Science Partners, Xora Innovation, ClavystBio

## Investors

- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series A
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A
- Xora Innovation (https://capitalatlas.ai/funds/xora-innovation) — Series A
- ClavystBio (https://capitalatlas.ai/funds/clavystbio) — Series A